These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8586489)

  • 1. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
    Greten TF; Eigler A; Sinha B; Moeller J; Endres S
    Int J Immunopharmacol; 1995 Jul; 17(7):605-10. PubMed ID: 8586489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
    Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
    Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
    Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
    J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
    Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
    Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents.
    Siegmund B; Eigler A; Moeller J; Greten TF; Hartmann G; Endres S
    Eur J Pharmacol; 1997 Feb; 321(2):231-9. PubMed ID: 9063693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
    Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.
    Eigler A; Siegmund B; Emmerich U; Baumann KH; Hartmann G; Endres S
    J Leukoc Biol; 1998 Jan; 63(1):101-7. PubMed ID: 9469479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
    Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
    Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
    Jung S; Zielasek J; Köllner G; Donhauser T; Toyka K; Hartung HP
    J Neuroimmunol; 1996 Aug; 68(1-2):1-11. PubMed ID: 8784254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice.
    Fischer W; Schudt C; Wendel A
    Biochem Pharmacol; 1993 Jun; 45(12):2399-404. PubMed ID: 8392340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.
    Beshay E; Croze F; Prud'homme GJ
    Clin Immunol; 2001 Feb; 98(2):272-9. PubMed ID: 11161985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
    Chi ZL; Hayasaka S; Zhang XY; Hayasaka Y; Cui HS
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2497-502. PubMed ID: 15277469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of IL-15-stimulated TNF-alpha production by rolipram.
    Kasyapa CS; Stentz CL; Davey MP; Carr DW
    J Immunol; 1999 Sep; 163(5):2836-43. PubMed ID: 10453029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the phosphodiesterase III inhibitor amrinone on cytokine and nitric oxide production in immunostimulated J774.1 macrophages.
    Németh ZH; Szabó C; Haskó G; Salzman AL; Vizi ES
    Eur J Pharmacol; 1997 Nov; 339(2-3):215-21. PubMed ID: 9473138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram.
    Kochetkova M; Burns FM; Souness JE
    Biochem Pharmacol; 1995 Dec; 50(12):2033-8. PubMed ID: 8849330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
    Schade FU; Schudt C
    Eur J Pharmacol; 1993 Jan; 230(1):9-14. PubMed ID: 8381357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.